P44/42 MAPK(ERK1/2) (Phospho Y205/222) Mouse mAb(4G3)

Key facts:

Catalog NO:	TDY600
Source :	Mouse
Type:	Monoclonal
Application:	IHC
Reactivity:	H, R, M
Isotype:	IgG1
MW(KDa):	44/42
Alternative Names:	MAPK, Mitogen-activated protein Kinase, PRKM2,MK01

Specifications:

Source

Mouse Monoclonal antibody is prepared by immunizing Synthetic Peptide coupled to KLH.

Specificity

The P44/42 MAPK(ERK1/2) Phospho Y205/222 Mouse Monoclonal antibody can recognize endogenous P44/42 MAPK(ERK1/2) Phospho Y205/222 proteins.

Storage

Store at -20°C. Stable for one year from the date of shipment.

Concentration

1mg/ml in PBS, pH 7.4, containing 0.02% sodium azide and 50% glycerol.

Dilutions

IHC 1:100-200

(Optimal dilutions should be determined by the end user)

Background:

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer.

Applications:

IHC	Immunohistochemical analysis of paraffin-embedded Human Colon Carcinoma Tissue using Phospho-ERK1/2 Y205/222（TDY600）Mouse mAb diluted at 1:200.

IHC	Immunohistochemical analysis of paraffin-embedded Human Breast Carcinoma Tissue using Phospho-ERK1/2 Y205/222（TDY600）Mouse mAb diluted at 1:200.

Contact information:

Company:	BEI JING TDY BIOTECH CO.,LTD.
Orders:	TDYbiotech@163.com
Website:	http://www.tdybio.com
Telephone:	010-80117836
Address:	Zhen Xin Road 36.Changping Distict,Beijing

Reactivity: H-Human R-Rat M-Mouse Mk-Monkey Dg-Dog Ch-Chicken Hm-Hamster Rb-Rabbit Sh-Sheep Pg-Pig

Applications: WB-Western blot IHC-Immunochemistry IF-Immunofluorescence IP-Immunoprecipitation ChIP-Chormatin Immunoprecipitation

Please note: All products are"FOR RESEARCH USE ONLY.NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES".